ePrints

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group

Lookup NU author(s): Professor Roderick Skinner

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2021 Elsevier LtdPatients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.

Publication metadata

Author(s): Mulder RL, Font-Gonzalez A, van Dulmen-den Broeder E, Quinn GP, Ginsberg JP, Loeffen EAH, Hudson MM, Burns KC, van Santen HM, Berger C, Diesch T, Dirksen U, Giwercman A, Gracia C, Hunter SE, Kelvin JF, Klosky JL, Laven JSE, Lockart BA, Neggers SJCMM, Peate M, Phillips B, Reed DR, Tinner EME, Byrne J, Veening M, van de Berg M, Verhaak CM, Anazodo A, Rodriguez-Wallberg K, van den Heuvel-Eibrink MM, Asogwa OA, Brownsdon A, Wallace WH, Green DM, Skinner R, Haupt R, Kenney LB, Levine J, van de Wetering MD, Tissing WJE, Paul NW, Kremer LCM, Inthorn J, Anderson RA, Barnbrock A, Beck JD, Bos AME, Calaminus G, Constine LS, Demeestere I, Denzer C, Grabow D, di Iorgi N, Hoefgen HR, Jahnukainen K, Kaatsch P, Kebudi R, Lambalk C, Langer T, Loonen J, Lorenzo A, Meacham LR, Meissner A, Mitchell RT, Nahata L, Ranft A, Dinkelman-Smit M, Stern C, Stutz-Grunder E, Tournaye H, van Dorp W, van Pelt AMM, de Vries A, Yu R

Publication type: Review

Publication status: Published

Journal: The Lancet Oncology

Year: 2021

Volume: 22

Issue: 2

Pages: e68-e80

Print publication date: 01/02/2021

Acceptance date: 02/04/2018

ISSN (print): 1470-2045

ISSN (electronic): 1474-5488

Publisher: Lancet Publishing Group

URL: https://doi.org/10.1016/S1470-2045(20)30595-7

DOI: 10.1016/S1470-2045(20)30595-7

Share